As such, alteration of CRMP2 activity via (S)-Lacosamide alone is unlikely to be a viable therapeutic target for CLN6-Batten disease, though it may prove to be beneficial when combined with other, synergistic compounds. This evidence concerns the gene DPYSL2 and juvenile neuronal ceroid lipofuscinosis.